Odyssey Health, Inc.

For the period ended Apr 30, 2025. Filed Jun 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Apr 30, 2025 · Filed Jun 13, 2025

ODYYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	April 30,	July 31,
	2025	2024
Assets
Current assets:
Cash	$3,186	$2,379
Research and development rebate due from Australian government	–	22,625
Prepaid expenses and other current assets	64,173	31,939
Total current assets	67,359	56,943
Investment in Oragenics, Inc. common stock	97,149	529,203
Total assets	$164,508	$586,146
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$1,477,577	$1,275,996
Accrued wages	1,916,943	1,648,586
Accrued interest	371,090	223,754
Asset purchase liability	1,125,026	1,125,026
Notes payable, officers and directors	100,000	100,000
Notes payable, net of unamortized beneficial conversion feature, debt discount and closing costs of $8,013 and $38,134	1,876,654	1,546,533
Total current liabilities	6,867,290	5,919,895
Commitments and contingencies	–	–
Stockholders’ deficit:
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding	–	–
Common stock, $0.001 par value, 500,000,000 shares authorized, 96,709,763 shares issued and outstanding	96,710	96,710
Additional paid-in capital	55,694,429	55,572,687
Accumulated deficit	(62,493,921)	(61,003,146)
Total stockholders’ deficit	(6,702,782)	(5,333,749)
Total liabilities and stockholders’ deficit	$164,508	$586,146

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.